Authors
Latest:
ESCRS 2023: Presbyopia treatment with microporation therapeutic technology by Ace Vision GroupAnnMarie Hipsley, DPT, PhD, met with Ophthalmology Times Europe to discuss Ace Vision Group's microporation therapeutic technology, used to treat presbyopia.
Latest:
Small-aperture IOL yields high satisfaction in retrospective reviewThe IC-8 IOL uses the small-aperture concept to extend cataract patients’ depth of focus. Patients report high approval and reduced spectacle dependence.
Latest:
It takes a village to beat visual system diseases in childrenCommunity support is the most important factor in ascertaining effective treatments for paediatric eye diseases.
Latest:
My first experiences with AT ELANA 841P and ARTEVO 850This article by Liem Trinh, MD highlights his experiences with the AT ELANA® 841P hydrophobic trifocal IOL and the ARTEVO® 750 and ARTEVO® 850 microscopes from ZEISS. Dr. Trinh discusses the benefits of the trifocal design of the AT ELANA 841P IOL and its ability to provide spectacle independence at all distances after cataract surgery. He also shares his positive experiences with the ARTEVO 850 microscope, which offers improved surgical visualization with RGB LED illumination and 3D viewing on a high dynamic range monitor. Additionally, Dr. Trinh discusses the potential benefits of integrated intraoperative optical coherence tomography (OCT) and the redesigned CALLISTO eye user interface.
Latest:
The truth about invisible posterior vitreous structuresUnderstanding vitreomacular interface diseases is key to treatment.
Latest:
Adapting our understanding of cerebral visual impairmentThe differential recruitment of the dorsal and ventral visual streams
Latest:
Real-world experience of OCT-A for retinal diagnoses and managementAs OCT-A devices become faster, the algorithms advance and the instrument costs decrease, more widespread utilisation in retina practices is likely.
Latest:
An accessible, free resource on genetic eye disease is changing patient educationMariya Moosajee, MBBS, BSc, PhD, FRCOphth, discusses how Gene Vision is improving patients' lives on a global scale
Latest:
Corneal nerve regeneration following semaglutide therapyA case report demonstrates independent effect of GLP-1 receptor agonist
Latest:
The complicated ins and outs of paediatric glaucomaEarly detection and diagnosis are key for these young patients
Latest:
Keratometry and total keratometry values are similar in healthy eyesAstigmatic values differed between K and TK readings
Latest:
Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditionsClinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2
Latest:
New IOL offers patients greater spectacle independence over wider rangePatients desire spectacle independence at all distances. Early experience with a recently launched IOL suggests that it can satisfy their demands for extended depth of vision.
Latest:
Personalising glaucoma surgery: The role of MIGSMinimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.
Latest:
A simple solution for complex corneasCorneal aberrations may occur more frequently than is generally appreciated, and they affect the visual outcomes following cataract surgery. Small-aperture optics provide a solution for a large category of patients who are otherwise not well served by complex IOLs.
Latest:
The ZEISS IOL Power Calculation Service. Providing guidance in complex casesAdvances in biometric technology and IOL calculation formulas have enabled refractive accuracy of cataract and clear lens exchange (CLE) surgery, but IOL power selection remains challenging in some cases. I have found that the ZEISS IOL Power Calculation Service (IPCS) is a valuable asset to help me in these uncertain situations.
Latest:
Expert on floppy iris syndrome offers practical pearls for successStrategies for the management and prevention of floppy iris syndrome include intraoperative interventions and recommendations on alternatives to tamsulosin for medical therapy in men with cataracts.
Latest:
IRISS registry study offers real-world outcomesInvestigators found that a fluocinolone acetonide implant maintained good real-world vision levels in patients with diabetic macular oedema who had good baseline vision.
Latest:
ESCRS 2023: OWL brings more of the 'world' to Ophthalmic World LeadersOWL's ESCRS 2023 event on Sunday, September 10, at 7 pm, promises an evening of visionary leadership and collaboration in ophthalmic innovation.
Latest:
Repeatable, high-quality imaging leads to better diabetic eye disease managementSD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.
Latest:
The evolving role of vitreosurgical simulators in surgical trainingNeed for accuracy results in optimisation of training for novice surgeons
Latest:
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of careBreakthrough technologies are raising the ceiling for functional visual outcomes
Latest:
Current approaches to treatment of uveitis with autoimmune diseaseUnderlying autoimmune disease alters uveitis therapy.
Latest:
Personalising glaucoma surgery: The role of MIGSMinimally invasive glaucoma surgery (MIGS) is appealing to glaucoma patients and surgeons; however, it should not be adopted without further high-quality research and careful reporting. Selection of the appropriate treatment for individual patients must be evidence based.
Latest:
Retinal imaging to detect Alzheimer disease: machine learning modelAn interdisciplinary team at Duke University has developed a proof-of-concept machine learning model capable of detecting symptomatic Alzheimer disease using multimodal retinal imaging data.
Latest:
Brolucizumab for neovascular AMD: Safety guidance and clinician perspectivesAlthough the majority of patients experience benefit with brolucizumab for the treatment of nAMD without severe adverse events, the risk of retinal vasculitis and/or retinal vascular occlusion needs to be balanced with potential benefits.
Latest:
Using swept-source OCT and OCT angiography to image choroidal tumoursSS-OCT provides a clear view of the eye’s internal structures and any abnormalities, helping to differentiate benign from malignant lesions.
